The Aurora kinase inhibitors in cancer research and therapy

Jonas Cicenas1,2,3

  • 1CALIPHO Group, Swiss Institute of Bioinformatics, CMU-1, rue Michel Servet, 1211, Geneva 4, Switzerland. j.cicenas@mapkinases.eu.

Insights

Small-molecule inhibitors targeting Aurora kinases (AURKs) are crucial for understanding cell division and treating cancers where these enzymes are deregulated. This review details AURK inhibitors for research and therapeutic applications.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • Kinase inhibitors are vital tools for studying cellular biochemical processes.
  • Aurora kinases (AURKs) are critical regulators of mitosis.
  • AURK deregulation (overexpression, amplification, etc.) is common in human cancers.

Purpose of the Study:

  • To review small-molecule Aurora kinase (AURK) inhibitors.
  • To discuss their applications in cancer research and therapy.
  • To aid researchers and clinicians in selecting appropriate inhibitors.

Main Methods:

  • Literature review of existing Aurora kinase inhibitors.
  • Analysis of their roles in cancer research.
  • Overview of clinical studies involving these inhibitors.

Main Results:

  • Identified various small-molecule inhibitors targeting AURKs.
  • Highlighted their utility in cancer research models.
  • Summarized clinical trial data for select inhibitors.

Conclusions:

  • Small-molecule AURK inhibitors are valuable for both fundamental research and cancer treatment.
  • The review provides guidance for selecting specific inhibitors.
  • Further clinical investigation of AURK inhibitors is warranted.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K